Quarterly report · Q3
3055.TEDINET S100Q3RS
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥198.6bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥188.6bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥2.2bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥1.7bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥146.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥136.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥142.2bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥89.0bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥81.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥57.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥856m | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥491m | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥808m | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥824m | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥109.94 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.72 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.4 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.44 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.3% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-12-31 | ¥1.9bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥46m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.8bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥819m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥10.2bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥10.2bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥14m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥362m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥825m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥25m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥49.2bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥48.9bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥379m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2m |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥295m |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥143.0bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥136.1bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6.9bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥208.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥198.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥3.3bn |
| Otherother segments | revenue | 2021-04-01 → 2021-12-31 | ¥1.3bn |
| Otherother segments | revenue external | 2021-04-01 → 2021-12-31 | ¥45m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥1.2bn |
| Otherother segments | segment profit | 2021-04-01 → 2021-12-31 | ¥264m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥10.3bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥10.3bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥10m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥122m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥1.0bn |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥331m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥700m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥60m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥47.2bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥46.9bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥350m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥875m |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥2.9bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥6m |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥272m |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥135.0bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥128.2bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥577m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥197.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥188.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥9.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 514
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash dividends paid fin cf | Prior1YTDDuration | -334000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -370000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -48000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -52000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -824000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -808000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 263000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 286000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 20434000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 21091000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 20697000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 21377000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 128169000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 46894000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E03003-000DispensingIndustryReportableSegmentsMember | 10289000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E03003-000NursingIndustryReportableSegmentsMember | 2847000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 331000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 45000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 188576000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 6836000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 350000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E03003-000DispensingIndustryReportableSegmentsMember | 10000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E03003-000NursingIndustryReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 700000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 1230000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9135000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 135005000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 47244000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E03003-000DispensingIndustryReportableSegmentsMember | 10300000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E03003-000NursingIndustryReportableSegmentsMember | 2853000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 1032000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 1275000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 197712000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 577000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 875000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E03003-000DispensingIndustryReportableSegmentsMember | 122000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E03003-000NursingIndustryReportableSegmentsMember | 272000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 60000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | 264000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2172000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 136130000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 48863000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03003-000DispensingIndustryReportableSegmentsMember | 10198000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03003-000NursingIndustryReportableSegmentsMember | 3004000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 362000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 46000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 198607000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 6891000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |